News

QuickLogic Corporation Delivers Q2 2025 Financial Insights

QuickLogic Corporation Delivers Q2 2025 Financial Insights

QuickLogic Corporation's Strong Performance in Q2 2025

QuickLogic Corporation (NASDAQ: QUIK), a leader in embedded FPGA (eFPGA) technology, ruggedized FPGAs, and Endpoint AI solutions, has disclosed its financial standing for the fiscal second quarter. With ongoing advancements across key sectors, QuickLogic showcases the impact of its recent innovations.

Highlights from Recent Developments

In a notable quarter, QuickLogic achieved several key milestones: a new revenue-generating eFPGA Hard IP License agreement for a customer’s Intel 18A test chip, a contract for a high-density eFPGA IP core, and the unveiling of the Aurora PRO FPGA User Tool, which enhances resource efficiency and speed. There are also significant enhancements being implemented in the Australis IP Generation tool, aimed at increasing value for customers.

Financial Overview for Fiscal Q2 2025

The company's total revenue from continuing operations reached $3.7 million in the second quarter of fiscal 2025. Unfortunately, this reflects a drop of 10% compared to the same period last year, alongside a 14.8% decrease relative to Q1 2025.

Breakdown of Revenue Sources

New product revenue stood around $2.9 million for this quarter, marking a decrease of $0.1 million, or 3.6%, from Q2 2024 and a decline of $0.8 million, or 22.1%, from Q1 2025. Meanwhile, revenue from mature products recorded $0.8 million this quarter, contrasting to $1.1 million in Q2 2024 and $0.6 million in Q1 2025.

Insights into Profitability and Margin Trends

The GAAP gross margin from continuing operations for Q2 2025 was reported at 25.9%, a substantial decline from 54.7% in the previous year and also lower than 43.4% in Q1 2025. Conversely, the non-GAAP gross margin was 31.0%, down from 58.2% in Q2 2024 and 47.1% in Q1 2025.

Operational Expenses Analysis

GAAP operating expenses from continuing operations amounted to $3.5 million, slightly up from $3.4 million in Q2 2024 but down from $3.9 million in Q1 2025. The non-GAAP operating expenses, by contrast, amounted to $2.5 million, down notably from $2.8 million a year prior and $3.0 million in the previous quarter.

Losses and Future Outlook

For the second quarter, QuickLogic experienced a GAAP net loss of $2.7 million, translating to a loss of $0.17 per share. This is contrasted with losses of $1.6 million, or $0.11 per share, last year, and $2.2 million, or $0.14 per share, the previous quarter.

Notes on Upcoming Strategies

Moving forward, QuickLogic aims to foster growth and innovation through its strategic partnerships and enhanced product offerings. The company is actively investing in research and development and aims to expedite the commercialization of its advanced AI solutions and FPGA technologies.

About QuickLogic Corporation

QuickLogic Corporation stands as a fabless semiconductor entity committed to revolutionizing embedded FPGA technology and building next-generation AI solutions. The company prides itself on its efficient and customizable low-power options designed for a wide range of markets, including aerospace, defense, industrial, computing, and consumer electronics.

Frequently Asked Questions

What were QuickLogic's total revenues for Q2 2025?

QuickLogic reported total revenues of $3.7 million for the second quarter of fiscal 2025.

How did QuickLogic's new product revenue perform?

New product revenue was approximately $2.9 million, a decrease of 3.6% compared to Q2 2024.

What was the GAAP gross margin for QuickLogic in Q2 2025?

The GAAP gross margin from continuing operations for Q2 2025 was reported at 25.9%.

What are the company’s future plans for product development?

QuickLogic plans to accelerate the introduction of new features in its Australis IP Generation tool and enhance its AI offerings.

How has the company's stock performance been impacted?

The earnings report indicates a net loss per share of $0.17, reflecting challenges in revenue generation and market conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 5

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Flavors of Portugal at the 2025 Port Wine Fest

Updated Category News Views 380

Port Wine Fest: A Celebration of Portuguese Culture The Port Wine Fest is an exciting festival dedicated to showcasing Portuguese wines and cuisine. In 2025, it will embark on its third edition with events scheduled across various vibrant cities, including San Francisco, Chicago, and New York City, creating an unforgettable experience that combines culture, food, and fine...

Continue Reading
Earnings Projections for 5E Advanced Materials to Watch

Updated Category News Views 118

Understanding 5E Advanced Materials’ Earnings Expectations 5E Advanced Materials (NASDAQ: FEAM) is gearing up to unveil its quarterly earnings report soon. Investors are keenly awaiting the details, as quarterly performance can significantly influence stock trends and market sentiment. Projected Earnings per Share Analysts are estimating an earnings per share (EPS) of...

Continue Reading
Verano Launches Adult Cannabis Sales in Connecticut's Waterbury

Updated Category News Views 111

Verano Launches Adult Use Cannabis Sales at Zen Leaf Waterbury Zen Leaf Waterbury has achieved a significant milestone by transitioning its dispensary from medical-only sales to hybrid sales, allowing for adult use cannabis sales in Connecticut. Location and Accessibility of Zen Leaf Waterbury Conveniently located at 237 East Aurora Street in Waterbury, the fifth largest...

Continue Reading
Innovative Medical Education Suite Introduced by Treatment.com AI

Updated Category News Views 176

Revolutionizing Medical Education with AI Integration Treatment.com AI Inc. is making strides in medical education by unveiling a cutting-edge platform designed to enhance clinical skills training. This innovation aims to provide a more immersive and effective educational experience for medical students. The newly launched Medical Education Suite (MES) represents a...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 24

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading